| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Friday’s Close |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | $105.71 | $113.53B | N/A |
3 Dividend-Paying Pharma Stocks to Buy Now
https://www.fool.com/investing/2019/10/15/3-dividend-paying-pharma-stocks-to-buy-now.aspx?source=iedfolrf0000001
Oct 15, 2019 - These aren't the highest payouts in the industry, but they have the best chance to steadily climb.
0
Lilly Gets FDA Approval for New Oral Tablets for Migraine
http://www.zacks.com/stock/news/563662/lilly-gets-fda-approval-for-new-oral-tablets-for-migraine?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-563662
Oct 14, 2019 - Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.
0
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals
http://www.zacks.com/stock/news/559573/pharma-stock-roundup-nvs-new-eye-drug-gets-fda-nod-nvo-gsk-pfe-sign-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-559573
Oct 11, 2019 - FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
0
3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates
http://www.zacks.com/stock/news/557902/3-big-drug-biotech-stocks-set-to-beat-q3-earnings-estimates?cid=CS-ZC-FT-earnings_esp-557902
Oct 10, 2019 - Here we highlight three bigshot drug/biotech companies, which are expected to deliver positive earnings surprises in Q3.
0
J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector
http://www.zacks.com/stock/news/557845/jj-jnj-to-start-q3-earnings-season-for-pharma-sector?cid=CS-ZC-FT-analyst_blog|earnings_preview-557845
Oct 10, 2019 - J&J's (JNJ) cancer drugs are expected to contribute significantly to third-quarter 2019 earnings. Generic/biosimilar headwinds are expected to hurt Pharma unit's sales.
0
Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan
http://www.zacks.com/stock/news/556224/gilead-gild-files-nda-for-ra-candidate-filgotinib-in-japan?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-556224
Oct 09, 2019 - Gilead's (GILD) new drug application for its JAK1 inhibitor filgotinib seeks treatment of rheumatoid arthritis in adult patients across Japan.
0
Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit
http://www.zacks.com/stock/news/553102/thermo-fisher-closes-api-site-buyout-fortifies-pharma-unit?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-553102
Oct 07, 2019 - Following the acquisition closure of GlaxoSmithKline's plant, Thermo Fisher (TMO) will continue to manufacture APIs for the same under a multi-year supply agreement.
0
Novo Nordisk Focuses on Pipeline Development Amid Competition
http://www.zacks.com/stock/news/552953/novo-nordisk-focuses-on-pipeline-development-amid-competition?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-552953
Oct 07, 2019 - Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.
0
The Zacks Analyst Blog Highlights: Bank of America, Home Depot, Philip Morris, NextEra and Eli Lilly
http://www.zacks.com/stock/news/548879/the-zacks-analyst-blog-highlights-bank-of-america-home-depot-philip-morris-nextera-and-eli-lilly?cid=CS-ZC-FT-press_releases-548879
Oct 04, 2019 - The Zacks Analyst Blog Highlights: Bank of America, Home Depot, Philip Morris, NextEra and Eli Lilly
0
Top Research Reports for Bank of America, Home Depot & Philip Morris
http://www.zacks.com/research-daily/547512/top-research-reports-for-bank-of-america-home-depot-philip-morris?cid=CS-ZC-FT-research_daily-547512
Oct 03, 2019 - Top Research Reports for Bank of America, Home Depot & Philip Morris
0